These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28267959)

  • 1. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension.
    Ogawa A; Satoh T; Tamura Y; Fukuda K; Matsubara H
    Am J Cardiol; 2017 May; 119(9):1479-1484. PubMed ID: 28267959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan.
    Ogawa A; Ejiri K; Matsubara H
    Life Sci; 2014 Nov; 118(2):414-9. PubMed ID: 24530872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.
    Tokunaga N; Ogawa A; Ito H; Matsubara H
    J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
    Sakao S; Tanabe N; Kasahara Y; Tatsumi K
    Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
    Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
    Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of prognosis and associated risk factors in pediatric idiopathic pulmonary arterial hypertension].
    Liu Q; Zhang C; Li QQ; Zhu Y; Zhang D; Zhao WG; Gu H
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):23-28. PubMed ID: 29342993
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.
    Takatsuki S; Nakayama T; Ikehara S; Matsuura H; Ivy DD; Saji T
    J Pediatr; 2017 Jan; 180():75-79.e2. PubMed ID: 27810156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension.
    Liu D; Wu BX; Sun N; Yan Y; Yuan P; Qu JM; Jing ZC
    Chest; 2016 Aug; 150(2):367-73. PubMed ID: 27001265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
    Luo Q; Jin Q; Zhao Z; Zhao Q; Yu X; Yan L; Zhang Y; Xiong C; Liu Z
    BMC Pulm Med; 2019 Dec; 19(1):257. PubMed ID: 31856792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoprostenol treatment in children with severe pulmonary hypertension.
    Lammers AE; Hislop AA; Flynn Y; Haworth SG
    Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension.
    Satoh M; Aso K; Nakayama T; Saji T
    Endocr J; 2017 Dec; 64(12):1173-1180. PubMed ID: 28890480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.